Guangdong By-health Biotechnology (300146.SZ) earned 585 million yuan in net profits in the first three quarters of 2015, up 22.16 percent year on year, according to the company's filing to the stock exchange on Wednesday.
Meanwhile, its operating revenue increased 28.56 percent year on year to 1.781 billion yuan during the reporting period. By the end of September, Central Huijin Investment Co. held 9.0871 million shares of the company, accounting for 1.25 percent of the total equity and ranking the top ten shareholders.
Latest comments